fluidigm.com (LAB): Price-to-Projected Revenue Ratio

Corporate company logo of Standard BioTools Corp (LAB)

Post-merger cost optimization is driving operational efficiency, as illustrated by the expected P/S chart for Standard BioTools Inc. (LAB). The value 3.00 indicates the current level of this metric. Revenue growth is fueled by the sale of systems and ancillary consumables. Business stability relies on government grants and the R&D budgets of pharmaceutical behemoths within the precision medicine sector.

fluidigm.com - LAB Market Cap to Projected Revenue (period 04/28/2023 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Standard BioTools Corp (LAB)

- current price and projected stock value:
Stock Price Standard BioTools|LAB - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Standard BioTools Corp|LAB - Business Value
- book value of equity indicators:
Book Value per Share Standard BioTools|LAB - Accounting Capitalization|Market Capitalization to Book Value Ratio fluidigm.com|LAB - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Standard BioTools Inc.|LAB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Standard BioTools Inc.|LAB - Company Aggregate Debt|Debt to Book Value Standard BioTools Corp|LAB - Company Long-Term Loans and Borrowings|Company Short-Term Debts Standard BioTools|Quick Ratio fluidigm.com
- financial results and valuation multiples details:
LAB - Net Financial Result|Expected Profit Standard BioTools Inc.|LAB - Market Cap to Earnings|Projected Price to Earnings Fluidigm|LAB - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Standard BioTools Corp|LAB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Standard BioTools|LAB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months fluidigm.com|LAB - Earnings per share growth in current year|Net earnings per share growth forecast for next year Standard BioTools Inc.
- sales and revenue indicators:
LAB - Company Gross Revenue|Company Future Sales Volume Standard BioTools|LAB - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Standard BioTools Corp
Fundamental company valuation:Standard BioTools (LAB)
Original product of Standard BioTools Corp

Standard BioTools Inc. (LAB) maintains a stable revenue stream from consumables sales, ensuring high cash flow predictability. This foundation allows for an accurate correlation between the current market value of the business and projected sales volumes. The metric measures the ratio of market capitalization to expected revenue, revealing the extent of the asset's overvaluation. Analyzing forward EV/Revenue helps investors promptly identify a dangerous gap between the share price and the business's actual growth rates.

Key competitors

Forward P/S Multiple A (Agilent)|Forward P/S Multiple Quest Diagnostics Inc. DGX|ILMN - Price-to-Projected Revenue Ratio|EXAS (Exact Sciences Inc.) - Market Cap to Projected Revenue|RVTY: Forward P/S Multiple|Market Cap to Projected Revenue BIO|NNNN (Anbio) - Forward P/S Multiple|Forward P/S Multiple Sotera Health Corp|Price-to-Projected Revenue Ratio QuidelOrtho Corp (QDEL)|OPK (OPKO Health Corp.) - Forward Price to Sales|Forward P/S Multiple CDNA (CareDx, Inc)|MRVI: Market Cap to Projected Revenue|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales CTKB (Cytek Biosciences Inc)|OSUR: Forward P/S Multiple|XGN (Exagen) - Price-to-Projected Revenue Ratio|MDXH (MDxHealth SA) - Forward P/S Multiple|luciddx.com (LUCD) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Prenetics Global (PRE)|IMDX - Market Cap to Future Revenue Ratio|Trinity Biotech - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio PRPH (ProPhase Labs Corp)|AIMD - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio codiagnostics.com|HeartSciences (HSCS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Biomerica Inc. (BMRA)|Price-to-Projected Revenue Ratio Cardio Diagnostics Holdings Inc.|Price-to-Projected Revenue Ratio ONCO|Price-to-Projected Revenue Ratio Virax Biolabs Group (VRAX)|Market Cap to Expected Sales Ratio bluejaydx.com|Aspira Women's Health Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales AXDX|centogene.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Enzo Biochem, Inc. ENZ|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue GENE|ME (23andMe) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Psychemedics Corp. (PMD)